<SEC-DOCUMENT>0001558370-20-003863.txt : 20200414
<SEC-HEADER>0001558370-20-003863.hdr.sgml : 20200414
<ACCEPTANCE-DATETIME>20200414094807
ACCESSION NUMBER:		0001558370-20-003863
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200414
FILED AS OF DATE:		20200414
DATE AS OF CHANGE:		20200414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		20790230

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tmb-20200414x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/14/2020 7:47:57 AM-->
<html>
	<head>
		<title>
			gmab_Current_Folio_6K_14Apr20
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt solid #000000 ;border-bottom:1pt solid #000000 ;text-indent:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:18pt;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:18pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Washington,&nbsp;D.C. 20549</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<br><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:18pt;">FORM&nbsp;6-K</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&nbsp;13a&#8209;16 OR&nbsp;15d&#8209;16</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">FOR THE&nbsp;MONTH OF&nbsp;APRIL 2020</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">COMMISSION FILE NUMBER 001-38976&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:18pt;">Genmab A/S<br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#333333;font-size:9.5pt;background-color: #FFFFFF;">(Exact name of Registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Kalvebod Brygge 43</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">1560 Copenhagen V</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Denmark</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">+45 70 20 27 28<br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#333333;font-size:9.5pt;background-color: #FFFFFF;">(Address of principal executive offices)</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&nbsp;20&#8209;F or&nbsp;Form&nbsp;40&#8209;F.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Form&nbsp;20&#8209;F&nbsp;</font><font style="display:inline;font-size:8pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40&#8209;F&nbsp;</font><font style="display:inline;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Indicate by check mark if the registrant is submitting the Form&nbsp;6&#8209;K in paper as permitted by Regulation&nbsp;S&#8209;T Rule&nbsp;101(b)(1)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Yes&nbsp;</font><font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;</font><font style="display:inline;font-size:8pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Indicate by check mark if the registrant is submitting the Form&nbsp;6&#8209;K in paper as permitted by Regulation&nbsp;S&#8209;T Rule&nbsp;101(b)(7)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Yes&nbsp;</font><font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;</font><font style="display:inline;font-size:8pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;background-color: #FFFFFF;">This report on Form&nbsp;6-K&nbsp;shall be deemed to be&nbsp;</font><font style="display:inline;">incorporated by reference</font><font style="display:inline;color:#000000;background-color: #FFFFFF;">&nbsp;in Genmab A/S&#x2019;s registration statements on&nbsp;Form&nbsp;S-8&nbsp;(File&nbsp;No.&nbsp;333-232693)&nbsp;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt solid #000000 ;border-bottom:3pt solid #000000 ;text-indent:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">SIGNATURE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:51.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">nthony</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">GENMAB A/S</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">BY:</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">/s/ Anthony Pagano</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Name: Anthony Pagano</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Title: Executive Vice President &amp; Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">DATE: April&nbsp;14, 2020</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">EXHIBIT&nbsp;INDEX</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;">
			<tr>
				<td valign="top" style="width:68.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">O</font></p>
				</td>
				<td valign="top" style="width:445.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit</font></p>
				</td>
				<td valign="top" style="width:445.25pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Description of Exhibit</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:445.25pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">99.1</font></p>
				</td>
				<td valign="top" style="width:445.25pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Company Announcement Dated&nbsp;April&nbsp;14, 2020: &nbsp;Genmab Announces Net Sales of DARZALEX</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:5pt;top:-4pt;position:relative;line-height:normal">&#xAE; &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">(daratumumab) for First Quarter of 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20200414xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/14/2020 7:47:56 AM-->
<html>
	<head>
		<title>
			gmab_Ex99_1_14Apr20
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Exhibit 99.1</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="tmb-20200414xex99d1g001.jpg" style="width: 2.103904in; height: 0.6249223in" alt="Picture 6"></font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 13pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;">Genmab Announces Net Sales of DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;font-size:7pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;"> (daratumumab) for First Quarter of 2020</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:12pt;">Company Announcement</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Net sales of DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"> in the first quarter of 2020 totaled USD 937 million</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc. </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Copenhagen, Denmark; April 14, 2020 &#x2013; Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab) as reported by Johnson &amp; Johnson were USD 937 million in the first quarter of 2020. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Net trade sales were USD 463 million in the U.S. and USD 474 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">About DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(daratumumab)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">DARZALEX&#xAE; (daratumumab) intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">1 &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. DARZALEX intravenous infusion is indicated for the treatment of adult patients in Europe: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S. In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;">www.DARZALEX.com</font></a>.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.&nbsp;&nbsp;Daratumumab triggers a person&#x2019;s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">1,2,3,4,5,6</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:12pt 0pt 0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

			&nbsp;

		</p>

		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">

			<tr>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Genmab A/S</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Tel: +45 7020 2728</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Company Announcement no. 17</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Kalvebod Brygge 43</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Fax: +45 7020 2729</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Page 1/3</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">21560 Copenhagen V, Denmark</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">www.genmab.com&nbsp;</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">CVR no. 2102 3884</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">LEI Code 529900MTJPDPE4MHJ122</font></p>

				</td>

			</tr>

		</table></div>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="tmb-20200414xex99d1g001.jpg" style="width: 2.103904in; height: 0.6249223in" alt="Picture 2"></font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 13pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;">Genmab Announces Net Sales of DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;font-size:7pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;"> (daratumumab) for First Quarter of 2020</font>

		</p>

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis, NKT-cell lymphoma and T-cell ALL. Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">About Genmab </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of three approved antibodies: DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Arzerra</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> (ofatumumab, under agreement with Novartis AG), for the treatment of certain chronic lymphocytic leukemia indications in the U.S., Japan and certain other territories and TEPEZZA&#x2122; (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development by Novartis for the treatment of relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform for generation of bispecific antibodies, the HexaBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform, which creates effector function enhanced antibodies, the HexElect</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.<br></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Contact:<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Marisol Peron, Corporate Vice President, Communications &amp; Investor Relations </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">T: +1 609 524 0065; E: <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;">mmp@genmab.com</font></a></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">For Investor Relations: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Andrew Carlsen, Senior Director, Investor Relations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">T: +45 3377 9558; E: <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;">acn@genmab.com</font></a>&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<br><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><a name="_Hlk34743654"></a></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:8pt;">This Company Announcement contains forward looking statements. The words &#x201C;believe&#x201D;, &#x201C;expect&#x201D;, &#x201C;anticipate&#x201D;, &#x201C;intend&#x201D; and &#x201C;plan&#x201D; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#x2019;s most recent financial reports, which are available on <a href="#\o"><font style="font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:8pt;">www.genmab.com</font></a> and the risk factors included in Genmab&#x2019;s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:8pt;">www.sec.gov</font></a>. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<br><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; the Y-shaped Genmab logo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; Genmab in combination with the Y-shaped Genmab logo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; HuMax</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; DuoBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; DuoBody in combination with the DuoBody logo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; HexaBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">HexaBody in combination with</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">the HexaBody logo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; &nbsp;</font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:12pt 0pt 0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

			&nbsp;

		</p>

		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">

			<tr>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Genmab A/S</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Tel: +45 7020 2728</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Company Announcement no. 17</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Kalvebod Brygge 43</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Fax: +45 7020 2729</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Page 2/3</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">21560 Copenhagen V, Denmark</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">www.genmab.com&nbsp;</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">CVR no. 2102 3884</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">LEI Code 529900MTJPDPE4MHJ122</font></p>

				</td>

			</tr>

		</table></div>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="tmb-20200414xex99d1g001.jpg" style="width: 2.103904in; height: 0.6249223in" alt="Picture 2"></font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 13pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;">Genmab Announces Net Sales of DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;font-size:7pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;"> (daratumumab) for First Quarter of 2020</font>

		</p>

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">DuoHexaBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; HexElect</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; and UniBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">. Arzerra</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;"> is a trademark of Novartis AG or its affiliates. DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;"> is a trademark of Janssen Pharmaceutica NV. TEPEZZA&#x2122; is a trademark of Horizon Therapeutics plc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;"> DARZALEX Prescribing information, September 2019. Available at: <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;font-size:8pt;">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s024lbl.pdf Last accessed September 2019</font></a></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;"> DARZALEX Summary of Product Characteristics, available at <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;font-size:8pt;">https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex</font></a> Last accessed October 2019</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">3</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;"> De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">4</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">5 &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">6 &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">Jansen, JH &nbsp;et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.&nbsp;Blood. 2012; 120(21): abstract 2974</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:12pt 0pt 0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

			&nbsp;

		</p>

		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">

			<tr>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Genmab A/S</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Tel: +45 7020 2728</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Company Announcement no. 17</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Kalvebod Brygge 43</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Fax: +45 7020 2729</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Page 3/3</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">21560 Copenhagen V, Denmark</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">www.genmab.com&nbsp;</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">CVR no. 2102 3884</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">LEI Code 529900MTJPDPE4MHJ122</font></p>

				</td>

			</tr>

		</table></div>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20200414xex99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20200414xex99d1g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ -OQMXSU
MV'Q-=V5K=R6=O;.$1(P 6X!W$]\Y_*NB^'OC:\UNYDTO4V$EPL?F13A0"X&
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M+87ZR'[.Q>/8Y7DXZ_E6BJ+VB?D<SP\OJ\X=6[_B:]>9_#;_ )&KQ+_UT_\
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ESBZMHI);G'RRSMN*_3  'UQ72TJDDDH1Z%8:E*4G6J;R_!'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
